An Immunoablative Regimen of Fludarabine and Cyclophosphamide Prevents Fully MHC-Mismatched Murine Marrow Graft Rejection Independent of GVHD

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 2 A, 2000, Pages 182-189

  Petrus, Matthew J ^a   Williams, Jonathan F ^a   Eckhaus, Michael A ^b   Gress, Ronald E ^a   Fowler, Daniel H ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Allogeneic bone marrow transplantation; Cyclophosphamide; Fludarabine; Graft rejection

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; VIDARABINE;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MOUSE; RADIATION EXPOSURE; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 0033657127     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70041-3     Document Type: Article

References (21)

1. Santos GW. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia - a review. Leuk Lymphoma. 1993;11(suppl 1):201-204.
2. Sparrelid E, Hagglund H, Remberger M, et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant. 1998;22:795-800.
3. Klingemann HG, Shepherd JD, Reece DE, et al. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies. Bone Marrow Transplant. 1994;14(suppl 4):S14-18.
4. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
5. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. 1992;175:405-413.
6. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83:2360-2367.
7. Reisner Y, Ben-Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci U S A. 1986;83:4012-4015.
8. Martin PJ. Determinants of engraftment after allogeneic marrow transplantation [editorial]. Blood. 1992;79:1647-1650.
9. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
10. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
11. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med. 1989;169:493-502.
12. Terenzi A, Aristei C, Aversa F, et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc. 1996;28:3101.
13. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048-3054.
14. Marshak-Rothstein A, Fink P, Gridley T, Raulet DH, Bevan MJ, Gefter ML. Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J Immunol. 1979;122:2491-2497.
15. Adjei AA, Dagnino L, Wong MM, Paterson AR. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol. 1992;31:71-75.
16. Gregoire V, Van NT, Stephens LC, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine rumor radiation response in vivo. Cancer Res. 1994;54:6201-6209.
17. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55:3352-3356.
18. Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996;38:261-268.
19. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998;100:142-146.
20. Tutschka PJ, Santos GW, Elfenbein GJ. Marrow transplantation in acute leukemia following busulfan and cyclophosphamide. Hamatol Bluttransfus. 1980;25:375-80.
21. Hiruma K, Hirsch R, Patchen M, Bluestone JA, Gress RE. Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood. 1992;79:3050-3058.